Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MYO 
Myomo Inc (MYO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MYO (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 55.02% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 161.25M USD | Price to earnings Ratio - | 1Y Target Price 9.25 |
Price to earnings Ratio - | 1Y Target Price 9.25 | ||
Volume (30-day avg) 527706 | Beta 1.54 | 52 Weeks Range 2.51 - 7.17 | Updated Date 04/4/2025 |
52 Weeks Range 2.51 - 7.17 | Updated Date 04/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.0233 | Actual -0.01 |
Profitability
Profit Margin -19% | Operating Margin (TTM) -2.03% |
Management Effectiveness
Return on Assets (TTM) -13.65% | Return on Equity (TTM) -36.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 144488318 | Price to Sales(TTM) 4.95 |
Enterprise Value 144488318 | Price to Sales(TTM) 4.95 | ||
Enterprise Value to Revenue 4.44 | Enterprise Value to EBITDA -0.82 | Shares Outstanding 34381100 | Shares Floating 26684910 |
Shares Outstanding 34381100 | Shares Floating 26684910 | ||
Percent Insiders 5.14 | Percent Institutions 59.19 |
Analyst Ratings
Rating 4.67 | Target Price 7.67 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Myomo Inc
Company Overview
History and Background
Myomo, Inc. was founded in 2004 as a spin-off from MIT. It focuses on developing and commercializing medical robotics for individuals with neurological disorders.
Core Business Areas
- MyoPro: MyoPro is a powered brace that restores function in paralyzed or weakened arms and hands, enabling individuals to perform activities of daily living.
Leadership and Structure
Paul R. Gudonis is the CEO. The company has a board of directors overseeing strategic direction. The structure includes departments for sales, marketing, engineering, and operations.
Top Products and Market Share
Key Offerings
- MyoPro: The MyoPro is a custom fitted powered orthosis. The product market share is difficult to determine due to the specialized nature of the medical device industry and competitive landscape. Competitors: ReWalk Robotics, Ekso Bionics.
Market Dynamics
Industry Overview
The industry involves rehabilitation robotics, assistive devices, and medical devices. Growth is driven by aging population and increasing prevalence of neurological disorders and stroke.
Positioning
Myomo focuses on upper extremity rehabilitation. Competitive advantages include the custom-fitted nature of their product and its focus on restoring function.
Total Addressable Market (TAM)
The TAM for upper extremity powered exoskeletons is estimated at several billion USD, considering the prevalence of stroke and other neurological conditions. Myomo holds a small portion of the TAM with opportunities to expand through reimbursement and market awareness.
Upturn SWOT Analysis
Strengths
- Proprietary MyoPro technology
- FDA cleared
- Focus on upper extremity function
- Custom-fitted device
Weaknesses
- Limited brand awareness
- High product cost
- Dependence on insurance reimbursement
- Limited market share
Opportunities
- Expansion into new geographies
- Development of new product applications
- Strategic partnerships with rehabilitation centers
- Increase in insurance coverage
Threats
- Competition from established medical device companies
- Changes in healthcare regulations
- Economic downturn impacting healthcare spending
- Technological advancements rendering products obsolete
Competitors and Market Share
Key Competitors
- RE(ReWalk Robotics)
- EKSO (Ekso Bionics)
Competitive Landscape
Myomo differentiates itself through its custom-fitted MyoPro device. It competes with larger companies with more established market presence. However the company has the benefit of FDA approval.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Myomo has experienced revenue growth in recent years, driven by increased adoption of MyoPro.
Future Projections: Future growth is projected to be driven by expansion into new markets and increased insurance coverage.
Recent Initiatives: Recent initiatives include expanding the sales force and securing additional insurance coverage.
Summary
Myomo is a company with innovative technology in rehabilitation robotics. While the MyoPro products have been cleared by the FDA for safety and effectiveness, and provide patients with opportunities to regain arm movement, limited brand recognition, reliance on insurance reimbursement, and competition could affect the company. Successful penetration into the market requires expanding insurance coverage and further commercialization.
Similar Companies
EKSO
Ekso Bionics Holdings Inc
EKSO
Ekso Bionics Holdings Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Please consult a financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myomo Inc
Exchange NYSE MKT | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-06-12 | Chairman, President & CEO Mr. Paul R. Gudonis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 184 | Website https://myomo.com |
Full time employees 184 | Website https://myomo.com | ||
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. It sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.